Weekly Spotlight
Medicaid Work Requirements: A Last-Minute Pivot That Could Cost Millions Their Coverage
On June 1, CMS released the long-anticipated Medicaid Community Engagement Interim Final Rule, implementing the One Big Beautiful Bill Act’s (OBBBA) Medicaid work requirements. The rule requires most able-bodied adult Medicaid enrollees ages 19-64 to document 80 hours per month of work, volunteering, or qualifying education beginning January 1, 2027. But a last-minute policy pivot—not the rule itself—ignited a firestorm across the health policy community.
The central controversy is the medical frailty exemption. OBBBA exempted enrollees who are “medically frail” from the work requirement. Prior CMS guidance suggested a relatively broad definition. The final rule tightened it significantly and added a requirement that enrollees re-document their frailty status every six months. POLITICO reported that doctors and patient advocates warn the documentation burden will fall hardest on people who are genuinely ill but lack support structures to meet recurring paperwork deadlines—including cancer patients, people with HIV, and adults with chronic conditions. NPR reported that advocates warn patients with cancer and HIV face real coverage loss risk under the narrowed exemption.
The pivot also caught states off guard. KFF Health News reported that states had been communicating with CMS for months and had already committed tens of millions of dollars to contractor systems built around prior guidance—guidance the June 1 rule effectively superseded. Bloomberg Law documented state frustration directly: the rule “goes beyond what Congress required” and is “inconsistent with guidance the government offered over the past year.” With less than seven months to the January 2027 implementation deadline, states now face costly and time-compressed system overhauls. POLITICO Pulse captured the mood this week: “caught by surprise.”
The coverage stakes are significant—and enrollment data released the same week made them more so. KFF data show that as of February 2026, children’s enrollment in Medicaid and CHIP has fallen below pre-pandemic levels for the first time—345,000 fewer children covered than in February 2020. KFF Health News reported the total decline at 2 million children since early 2025, with one expert warning this represents “a disaster in the making” given that the policy mechanisms most likely to accelerate that erosion have not yet taken effect.
CMS Administrator Mehmet Oz, in a June 2 POLITICO interview, framed the rule as empowering enrollees through “a path to prosperity.” Inside Health Policy reported that advocates say the rule breaks lawmakers’ promises that cancer patients and other severely ill enrollees would be protected. House Energy & Commerce Chairman Guthrie issued a statement supporting the rule.
Tags: #PAYER #PATIENT #PROVIDER #HOSPITAL
Centers for Medicare and Medicaid Services (CMS)
No Surprises Act: New IDR Rules, Fee Cuts, and a Fraud Allegation
CMS finalized changes to the No Surprises Act’s independent dispute resolution (IDR) process, reducing the per-party administrative fee from $115 to $15 and capping batched dispute submissions at 50 line items. The rule standardizes open negotiation communications and outlines an IDR Gateway platform launching in phases in 2026. STAT+ warned the dramatically lower filing cost could worsen the flood of provider disputes rather than reduce them. Separately, Highmark Health sued IDR entity HaloMD, alleging it used “sham letters” to manipulate arbitration outcomes.
Source(s): Fierce HealthcareCMSSTAT+STAT+ Tags: #HOSPITAL #PROVIDER #PAYER
Medicare Advantage Crosses 55% Enrollment Milestone
More than half of eligible Medicare beneficiaries—55%—are now enrolled in Medicare Advantage plans, surpassing traditional Medicare enrollment for the first time. KFF’s annual brief documents the milestone alongside growing plan concentration and prior authorization variability across markets.
Source(s): KFFKFF Tags: #PAYER #PATIENT
OIG: CMS May Have Overpaid MA Plans $462M for Unsupported Stroke Diagnoses
The HHS Office of Inspector General found CMS may have overpaid Medicare Advantage plans $462 million for acute stroke diagnoses lacking supporting clinical documentation, raising questions about MA risk adjustment integrity and CMS oversight of plan coding practices.
Source(s): Becker’s Hospital ReviewFierce Healthcare Tags: #PAYER
OBBBA Medicaid Cuts Pose Largest Credit Risk to Nonprofit Hospitals in Years
HFMA analysis flags Medicaid cuts legislated in OBBBA as the largest single credit risk to the not-for-profit hospital sector in recent history, projecting significant DSH payment reductions and uncompensated care increases for high-Medicaid-volume hospitals. Health systems are already reporting early payer mix shifts as the law’s effects begin.
Source(s): HFMA Tags: #HOSPITAL #PAYER
Medicare’s GLP-1 Bridge: $50/Month Obesity Drugs, Unknown Cost to Taxpayers
CMS’s Medicare GLP-1 Bridge program launches July 1, offering Wegovy and Zepbound for $50/month to eligible Part D enrollees through December 2027. The program operates outside standard Part D—costs fall entirely on taxpayers rather than insurers. CMS has not disclosed projected program costs. UnitedHealthcare separately announced it will eliminate nearly two-thirds of its pediatric prior authorization requirements by end of year.
Source(s): STAT+Fierce Healthcare Tags: #PAYER #PATIENT
Prior Authorization Reform Exposes a Gap Between Speed and Payment
MedCity News examines the disconnect between faster prior authorization decisions—required under CMS rules—and unchanged payment timelines, arguing that reform has accelerated approvals without fixing the billing cycles that delay actual reimbursement.
Source(s): MedCity News Tags: #HOSPITAL #PROVIDER #PAYER
Cities and Physicians Sue CMS Over ACA Marketplace Rule Changes
A coalition of cities, physicians, and small businesses filed suit challenging CMS rule changes to the ACA marketplace, alleging the changes will cause at least 1 million people to lose marketplace coverage.
Source(s): Becker’s Hospital Review Tags: #PAYER #PATIENT
Telehealth Physician Independence Under Legal Scrutiny
STAT investigates whether direct-to-consumer telehealth physicians are truly independent from the platforms that employ them. Ongoing litigation challenges the corporate practice of medicine model used by major DTC telehealth companies, with implications for how telehealth is regulated and reimbursed.
Source(s): STAT Tags: #PROVIDER #PAYER
Food and Drug Administration (FDA)
TAVR: New Clinical Evidence, A First-in-Human Case, and an Industry Call to Action
Three threads defined TAVR news this week. First, new real-world data show a growing share of TAVR procedures are being performed in patients under 65—a population most guidelines say should receive surgical replacement given TAVR’s durability constraints over multi-decade lifespans—prompting an advocacy group to call on CMS and the administration to “stop getting in between” physicians and guidelines-based care. Second, a first-in-human JSCAI case report documents successful TAVR with the Navitor self-expanding valve in a patient with a left ventricular assist device—a technically complex scenario representing an emerging patient population. Third, Modern Healthcare reports Boston Scientific’s $1.5 billion investment in MiRus LLC signals an aggressive push into the TAVR market, directly targeting Edwards Lifesciences’ lead position.
Source(s): Cardiovascular BusinessCardiovascular BusinessJSCAIModern Healthcare Tags: #DEVICE #PROVIDER
SAVR After TAVR: Risk Assessment for a Growing Clinical Challenge
As TAVR expands into younger patient populations, clinicians face increasing numbers of complex redo open-heart procedures. Cardiovascular Business covers an updated risk calculator for evaluating surgical risk in SAVR-after-TAVR cases, alongside a newsletter roundup of TAVR highlights including self-expanding valve durability data, a new leaflet-splitting technique, and implant depth outcomes.
Source(s): Cardiovascular BusinessCardiovascular BusinessCardiovascular Business Tags: #DEVICE #PROVIDER
Edwards Gets FDA Approval for First Dedicated Tricuspid Surgical Valve
Edwards Lifesciences received FDA approval for the Triformis Resilia—the first surgical valve designed specifically for the tricuspid position. The valve uses Edwards’ Resilia anticalcification tissue platform and addresses a longstanding gap in surgical options for tricuspid valve disease.
Source(s): MedTech DiveMedical Design & Outsourcing Tags: #DEVICE #PROVIDER
GLP-1 Medications Linked to Fewer Cardiac Events in Obesity-Autoimmune Patients
AHA research highlight: adults with both obesity and an autoimmune disease who took GLP-1 receptor agonist medications had fewer cardiac events, fewer ED visits, and fewer hospitalizations than comparable patients not on the drugs, adding to GLP-1’s expanding cardiovascular evidence base.
Source(s): AHA Newsroom Tags: #DEVICE #PROVIDER
FDA Roundup: Voucher Program Draws Skepticism; Device and Drug Policy Updates
At the first public hearing for FDA Commissioner Makary’s Commissioner’s National Priority Voucher (CNPV) program, industry expressed cautious support while patient advocates raised concerns about access. PhRMA argued FDA lacks statutory authority to factor drug pricing into voucher eligibility; STAT+ reported the hearing drew “mostly thumbs-down” responses. Additional updates: FDA issued updated guidance on economic information sharing between manufacturers and payers; issued a notice of intent to exempt certain unclassified devices from premarket notification; early QMSR inspections are highlighting risk management as a top observation area; and the House is considering tariff and cancer drug shortage amendments to the FY2027 FDA spending bill.
Source(s): Fierce BiotechInside Health PolicySTAT+STAT+RAPSInside Health Policy Tags: #DEVICE #DRUG
Department of Health and Human Services (HHS)
Vaccine Policy Roundup: Trump EO, Contested Studies, and a Rebuke from Cassidy
President Trump signed an executive order directing HHS to overhaul the childhood vaccine schedule review process. An attorney involved in related litigation told Inside Health Policy the EO is “toothless” as a legal matter. The Guardian reported that three studies RFK Jr. and allies have used to justify vaccine policy changes have faced retractions or significant credibility challenges. Sen. Cassidy issued a formal rebuke of Kennedy over the resurgence of vaccine-preventable diseases.
Source(s): Becker’s Hospital ReviewInside Health PolicyThe GuardianThe Hill Tags: #ALL
RFK Jr.: Disengaged on Management, Pursuing Medical Records Access
The NYT reports HHS Secretary Kennedy has shown little interest in departmental operations, delegating most decisions to political appointees while creating a management vacuum across the department. Kennedy is separately pursuing federal access to most Americans’ medical records through CMS administrative data to research autism and vaccine safety, drawing privacy objections from former HHS officials.
Source(s): NYTMedPage TodaySTAT+ Tags: #ALL
HHS Appropriations: House Bill Cuts Department, Spares NIH
The House Appropriations subcommittee advanced a FY2027 HHS spending bill that cuts overall HHS funding by approximately 4% while providing a small NIH increase—a notable break from earlier proposed NIH cuts. The White House endorsed the House approach. Full committee markup is expected this week.
Source(s): Inside Health PolicyPOLITICO PulseInside Health Policy Tags: #ALL
NIH and HHS Research Independence Under Pressure
The Trump administration is moving to strip civil service job protections from top NIH officials and hundreds of HHS employees under an expanded Schedule Policy/Career executive order. Science reported that HHS political appointees are now reviewing the scientific content of NIH grant decisions —a break from longstanding research independence norms. A new OMB rule would also give political appointees authority over federal grant awards more broadly.
Source(s): STAT+Inside Health PolicyScienceAP News Tags: #ALL
Title X / Planned Parenthood: 57 Clinics Closed Since January 2025
KFF documents 57 Planned Parenthood clinic closures or consolidations across 20 states since January 2025, reducing Title X provider network capacity and access for low-income patients.
Source(s): KFF Tags: #PATIENT #PROVIDER
Drug Pricing Roundup: MFN Deals, TrumpRx, and the PCMA Counteroffensive
President Trump announced TrumpRx expansion, adding 160 drugs to his direct-to-consumer pricing platform. CMS Administrator Oz said all MFN drug pricing deals will expire when the administration ends. Brand-name drug prices continue to rise at launch in the US while falling abroad amid the MFN push. PCMA launched a seven-figure ad campaign to shift policymaker focus toward drug manufacturers rather than PBMs.
Source(s): The HillInside Health PolicyFierce PharmaInside Health Policy Tags: #DRUG #PAYER
HHS Personnel Notes
Trump nominated a hospital finance reform advocate as HHS Assistant Secretary. CMS Administrator Oz deflected questions about Bill Pulte’s appointment to a senior HHS-adjacent role; Oz also addressed questions about Trump’s frequent physician visits.
Source(s): Inside Health PolicyThe HillThe Hill Tags: #ALL
Heard on the Hill
SCOTUS Backs Generic Drug Maker in Skinny Labeling Case
The Supreme Court ruled in favor of a generic drug manufacturer in a closely watched “skinny labeling” case, upholding the practice of marketing generic drugs for a subset of a brand drug’s approved indications to avoid patent infringement. The ruling has broad implications for generic drug competition and hospital formulary management. The House is now weighing related generic Rx reform legislation.
Source(s): STAT+Inside Health Policy
Tags: #DRUG #HOSPITAL
Cassidy Calls Out RFK Jr., Promotes Health Agenda
Sen. Bill Cassidy (R-LA), a physician and Senate HELP Committee chair who recently lost his primary, has sharpened his public criticism of HHS Secretary Kennedy—calling him out over the resurgence of vaccine-preventable diseases and urging the administration to engage more seriously on health priorities.
Source(s): MedPage TodayInside Health Policy
Tags: #ALL
SCOTUS Splits on Vaccine Mandates; House Preserves SAMHSA Funding
The Supreme Court punted on one vaccine mandate case while the DOJ sided with New York in another, leaving the legal landscape on mandates unresolved. The House Appropriations bill separately preserved SAMHSA funding the administration had proposed eliminating.Source(s): Inside Health PolicyInside Health Policy
Tags: #ALL
Notable Notes
340B: Eli Lilly’s Ultimatum and the Industry at an Inflection Point
Eli Lilly gave hospitals a hard deadline—submit 340B claims data by June 8 or lose discounted pricing on Lilly products. The ultimatum affected over 1,000 hospitals and prompted a coalition to urge HHS to intervene before discounts were revoked. Becker’s separately published a mid-year 340B program tracker covering active litigation and policy shifts.Source(s): KFF Health NewsFierce HealthcareHealthcare DiveBecker’s Hospital ReviewFierce PharmaInside Health PolicyBecker’s Hospital Review Tags: #HOSPITAL #DRUG
AI in Healthcare: Policy, Procurement, and Pushback
A roundup of AI policy developments this week:
- House Republicans advance data privacy bill touching on AI, setting aside a larger comprehensive framework
- Trump signs AI cybersecurity executive order with healthcare implications
- STAT+ examines the medical billing AI arms race between providers and insurers
- Trump administration seeks preview access to AI models that could shape Medicare coverage decisions
- NCQA recruiting members for an AI in prior authorization learning collaborative
Tags: #HOSPITAL #PROVIDER #PAYER
$300B Patent Cliff Could Reshape Hospital Drug Spending
A Moody’s analysis projects approximately $300 billion in pharmaceutical revenue from rated companies will face patent expiration in the next several years, with significant downstream effects on hospital formulary management and drug procurement costs.
Source(s): Becker’s Hospital Review Tags: #HOSPITAL #DRUG
1 in 5 Americans With Private Insurance Report Coverage Denials
KFF survey: 21% of adults with private health insurance reported having a claim denied in the past year, underscoring ongoing concerns about prior authorization and claims management practices across commercial insurance markets.
Source(s): Becker’s Hospital Review Tags: #PAYER #PATIENT
CereVasc Raises $85M for Minimally Invasive Brain Shunt
CereVasc closed an $85 million Series C round to advance its eShunt—a minimally invasive transcatheter device for treating hydrocephalus designed to reduce the high revision rates that plague traditional shunt surgery.
Source(s): MedCity News Tags: #DEVICE #PATIENT